Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer

A Multicenter, Prospective, Randomized Phase II Trial Evaluating Trastuzumab, Pertuzumab, Docetaxel Combined With QL1706 Versus Combined With Carboplatin as Neoadjuvant Therapy for Early or Locally Advanced HER2+ Breast Cancer

This study is a multicenter, prospective, randomized phase II trial designed to observe and evaluate the efficacy and safety of trastuzumab, pertuzumab, docetaxel combined with QL1706 versus combined with carboplatin as neoadjuvant therapy in patients with operable or locally advanced HER2-positive breast cancer.

Study Overview

• Status: Not yet recruiting
• Conditions: Breast Cancer
• Intervention / Treatment: Drug: QL1706 injection; Drug: Trastuzumab (or biosimilar); Drug: Pertuzumab (or biosimilar); Drug: Docetaxel; Drug: Carboplatin

Detailed Description

This multicenter, randomized phase II trial evaluates the efficacy and safety of neoadjuvant therapy with trastuzumab, pertuzumab, and docetaxel plus QL1706 versus the same regimen plus carboplatin in patients with operable or locally advanced HER2-positive breast cancer.

The study will enroll 188 subjects, randomly assigned 1:1 to either the QL1706 combination arm or the carboplatin combination arm, stratified by nodal status and hormone receptor status (<10% vs ≥10%). Both treatment groups will receive four 3-week cycles of assigned therapy followed by surgical resection and response assessment. Postoperative adjuvant treatment will be administered according to investigator discretion and guideline recommendations.

• Study Type: Interventional
• Enrollment (Estimated): 188
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Jin Zhang; Phone Number: +8618622221173; Email: zhangjintjmuch1@163.com

Study Locations

• China
  • Guangdong
    • Guangzhou, Guangdong, China
      • Guangdong Provincial People's Hospital
      • Principal Investigator: Kun Wang
      • Contact: Kun Wang; Phone Number: 86+13922118086; Email: gzwangkun@126.com
    • Guangzhou, Guangdong, China
      • The First Affiliated Hospital, Sun Yat-sen University (FAH-SYSU)
      • Contact: Ying Lin; Phone Number: 86+13076873871; Email: frostlin@hotmail.com
      • Principal Investigator: Ying Lin
  • Hebei
    • Shijiazhuang, Hebei, China
      • The Fourth Hospital of Hebei Medical University
      • Principal Investigator: Cuizhi Geng
      • Contact: Cuizhi Geng; Phone Number: 86+18435221693; Email: cuizhi_geng@163.com
  • Henan
    • Luoyang, Henan, China
      • The First Affiliated Hospital of Henan University of Science & Technology
      • Contact: Limin Wei; Phone Number: 86+13783100995; Email: 13783100995@163.com
      • Principal Investigator: Limin Wei
    • Nanyang, Henan, China
      • Nanyang Central Hospital
      • Principal Investigator: Hao Zhang
      • Contact: Zheng Wang; Phone Number: 86+13723010881; Email: 20090957@qq.com
  • Sichuan
    • Chengdu, Sichuan, China
      • The West China Second University Hospital of Sichuan University (WCSUH- SCU)
      • Principal Investigator: Rutie Yin
      • Contact: Rutie Yin; Phone Number: 86+18180609015; Email: hxyrtgcp@126.com
  • Tianjin Municipality
    • Tianjin, Tianjin Municipality, China
      • Tianjin Medical University Cancer Institute and Hospital
      • Principal Investigator: Jihui Hao
      • Principal Investigator: Jin Zhang
      • Contact: Jin Zhang; Phone Number: +8618622221173; Email: zhangjintjmuch1@163.com
  • Zhejiang
    • Jiaxing, Zhejiang, China
      • Affiliated Hospital of Jiaxing University
      • Contact: Caiping Chen; Phone Number: 86+13967370819; Email: luyun6@163.com
      • Principal Investigator: Caiping Chen

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Signed informed consent and compliant.
2. Age 18-70 years.
3. ECOG PS 0-1; life expectancy >6 months.
4. Histologically/cytologically confirmed primary breast cancer.
5. Primary tumor >2cm (by local standard assessment) or node-positive disease.
6. AJCC 8th edition Stage II-IIIC (T2-T4 any N, or any T N1-3 M0) unilateral invasive breast cancer.
7. Confirmed HER2-positive (IHC 3+ or ISH positive). Note: Patients with HER2-negative primary tumor but HER2-positive nodes are eligible.
8. At least one measurable lesion per RECIST 1.1.
9. Agreement to undergo surgery if indicated after neoadjuvant therapy.
10. Willing to provide tumor tissue for biomarker analysis.

11. Adequate organ function:

    • ANC ≥1.5×10⁹/L; PLT ≥100×10⁹/L; HGB ≥90 g/L

    • Albumin ≥30 g/L

      -. TBIL ≤1.5×ULN; ALT/AST ≤2.5×ULN (≤5×ULN if liver metastases); AKP ≤2.5×ULN

    • Creatinine ≤1.5×ULN
    • PT/APTT/INR ≤1.5×ULN (or within therapeutic range if on anticoagulants)
12. For women of childbearing potential: negative pregnancy test within 7 days prior to treatment; must not be breastfeeding.
13. Use of highly effective contraception during and for 3 months after treatment.

Exclusion Criteria:

1. Stage IV metastatic breast cancer or patients deemed ineligible for curative surgery after neoadjuvant therapy.
2. Inflammatory breast cancer.
3. Other malignancies within 3 years, except: those treated with surgery alone and disease-free for 5 years; cured cervical carcinoma in situ, non-melanoma skin cancer, or superficial bladder cancer [Ta, Tis, T1].
4. Prior anti-tumor therapy (chemotherapy, endocrine, anti-HER2) or breast surgery for breast cancer within 3 years (excluding diagnostic biopsy).
5. Major surgery or significant traumatic injury within 28 days before treatment (excluding diagnostic biopsy).
6. Active or history of autoimmune diseases (e.g., autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism). Exceptions: vitiligo, childhood asthma in complete remission without intervention in adulthood.
7. Current use of immunosuppressants or systemic corticosteroids (>10mg/day prednisone equivalent) within 2 weeks prior to enrollment.
8. History of severe hypersensitivity to monoclonal antibodies.
9. Known central nervous system metastases.

10. Poorly controlled concurrent illnesses, including:

    • Uncontrolled hypertension (SBP>150 or DBP>100 mmHg on medication) or history of hypertensive crisis/encephalopathy.
    • History of heart failure or systolic dysfunction (LVEF <55%).
    • Myocardial ischemia/infarction (≥Grade 2), arrhythmias (QTc≥450ms M, ≥470ms F), or CHF (≥NYHA Class II).
    • Angina requiring medication; clinically significant valvular disease.
    • Active HCV (RNA+), HIV+, syphilis (unless cured), or HBV (HBsAg+ with HBV DNA≥2000 IU/ml or positive qualitative test).
11. Use of Chinese patent medicines with approved anti-tumor indications within 2 weeks prior to treatment.
12. Significant bleeding tendency or clinical bleeding within 3 months; positive fecal occult blood requiring gastroscopy if persistently positive.
13. Tumor invasion or high risk of invasion into major vessels, potentially causing fatal hemorrhage.
14. Pleural, peritoneal, or pericardial effusion requiring drainage (eligible if stable after drainage).
15. Arterial/venous thromboembolic events within 6 months (e.g., CVA, TIA, DVT, PE).
16. Known hereditary or acquired bleeding/thrombotic tendencies (e.g., hemophilia).
17. Severe, non-healing wounds, active ulcers, or untreated fractures.
18. Urinary protein ≥++ confirmed by 24-hour urine protein >1.0g.
19. Active infection, unexplained fever ≥38.5°C within 7 days, or baseline WBC >15×10⁹/L.
20. History of drug abuse or psychiatric disorders.
21. Participation in other anti-tumor drug trials within 4 weeks.
22. Allergy to any study drug or its components.
23. Any condition deemed by the investigator to pose a safety risk or affect study completion.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: QL1706 arm; Trastuzumab, pertuzumab, docetaxel combined with QL1706, q3w, for a total of 4 cycles	Drug: QL1706 injection; On Day 1 of each cycle at a dose of 5 mg/kg, IV infusion; Drug: Trastuzumab (or biosimilar); On Day 1 of each cycle; 8 mg/kg IV loading dose followed by 6 mg/kg IV every 3 weeks; Drug: Pertuzumab (or biosimilar); On Day 1 of each cycle; 840 mg IV loading dose followed by 420 mg IV every 3 weeks; Drug: Docetaxel; On Day 1 of each cycle at a dose of 75 mg/m², IV infusion
Active Comparator: Standard therapy arm; Trastuzumab, pertuzumab, docetaxel combined with carboplatin, q3w, for a total of 4 cycles	Drug: Trastuzumab (or biosimilar); On Day 1 of each cycle; 8 mg/kg IV loading dose followed by 6 mg/kg IV every 3 weeks; Drug: Pertuzumab (or biosimilar); On Day 1 of each cycle; 840 mg IV loading dose followed by 420 mg IV every 3 weeks; Drug: Docetaxel; On Day 1 of each cycle at a dose of 75 mg/m², IV infusion; Drug: Carboplatin; On Day 1 of each cycle at a dose of AUC = 4, IV infusion

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pathological complete response (pCR) rate using the definition of ypT0/Tis ypN0 (i.e., no invasive residual in breast or nodes; noninvasive breast residuals allowed) at the time of definitive surgery	pCR rate (ypT0/Tis ypN0) is defined as the percentage of participants without residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy by current American Joint Committee on Cancer (AJCC) staging criteria assessed by the local pathologist at the time of definitive surgery.	Up to approximately 16-18weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall survival (OS)	OS is defined as the time from randomization to death due to any cause.	Up to approximately 5 years
pCR rate using the definition of ypT0/Tis (i.e., no invasive residual in breast or nodes; noninvasive breast residuals allowed) at the time of definitive surgery	pCR rate (ypT0/Tis) is defined as the percentage of participants without invasive cancer in the breast irrespective of ductal carcinoma in situ or nodal involvement following completion of neoadjuvant systemic therapy by current AJCC staging criteria assessed by the local pathologist at the time of definitive surgery	Up to approximately 16-18 weeks
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1)	ORR is defined as the percentage of participants in the analysis population who achieve confirmed complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.	Up to approximately 12 weeks
Event Free Survival	EFS is defined as the time from randomization to any of the following events: preoperative disease progression as determined by the investigator according to RECIST v1.1 - any evidence of contralateral in situ disease is not considered disease progression (PD), while all evidence of contralateral invasive disease is considered PD; postoperative disease recurrence (local, regional, distant, or contralateral); death from any cause. (Whichever occurs first)	Up to approximately 5 years
Disease-free Survival	DFS is defined as the time from date of surgery (date of no disease) to the first documentation of progressive disease (local, regional, distant, or contralateral) or death.	Up to approximately 5 years
Breast-conserving surgery rate	Breast-conserving surgery rate is the proportion of patients who underwent breast-conserving surgery among all patients who underwent surgery.	Up to approximately 16-18 weeks
Radical resection rate	The proportion of patients who achieved radical resection among all patients.	Up to approximately 16-18 weeks

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
AEs, TRAEs, SAEs	Incidence and severity of adverse events (AE), treatment-related adverse events (TRAE), serious adverse events (SAE) from cycle 1 day 1 until 30 days post-surgery.	Up to approximately 21-23 weeks

Collaborators and Investigators

• Sponsor: Tianjin Medical University Cancer Institute and Hospital

Study record dates

Study Major Dates

• Study Start (Estimated): December 15, 2025
• Primary Completion (Estimated): December 31, 2027
• Study Completion (Estimated): December 31, 2032

Study Registration Dates

• First Submitted: November 17, 2025
• First Submitted That Met QC Criteria: November 17, 2025
• First Posted (Estimated): November 24, 2025

Study Record Updates

• Last Update Posted (Actual): November 28, 2025
• Last Update Submitted That Met QC Criteria: November 23, 2025
• Last Verified: November 1, 2025

More Information

Terms related to this study

• Keywords: breast cancer; neoadjuvant therapy; Trastuzumab; Pertuzumab; HER2+; QL1706
• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Skin Diseases; Breast Diseases; Skin and Connective Tissue Diseases; Breast Neoplasms; Amino Acids, Peptides, and Proteins; Proteins; Organic Chemicals; Hydrocarbons; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Terpenes; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Serum Globulins; Globulins; Coordination Complexes; Taxoids; Cyclodecanes; Diterpenes; Biological Products; Complex Mixtures; Docetaxel; Trastuzumab; Carboplatin; pertuzumab; Biosimilar Pharmaceuticals
• Other Study ID Numbers: QL-BC-QIBA-1005

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No